We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

3 hedge funds and large institutions have $7.45M invested in Hepion Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding

Funds holding: 1 → 3 (+2)

136% more capital invested

Capital invested by funds: $3.16M → $7.45M (+$4.29M)

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EI
EAM Investors
California
+$2.36M
2
TCIM
TIAA CREF Investment Management
New York
+$2.36M

Top Sellers

Rank Fund Capital Flow
1
EVC
Eidelman Virant Capital
Missouri
-$76K
2
CS
Credit Suisse
Switzerland
-$61K
3
CC
Callan Capital
California
-$52K
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
1
EAM Investors
California
$3.11M +$2.36M +1 New
TCIM
2
TIAA CREF Investment Management
New York
$2.08M +$2.36M +1 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.12M – – –
Morgan Stanley
4
Morgan Stanley
New York
$393K – – –
PFS
5
Prospera Financial Services
Texas
$181K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$157K – – –
BFA
7
BlackRock Fund Advisors
California
$126K – – –
Cambridge Investment Research Advisors
8
Cambridge Investment Research Advisors
Iowa
$63K – – –
Bank of New York Mellon
9
Bank of New York Mellon
New York
$56K – – –
SIM
10
Spark Investment Management
New York
$49K – – –
HighTower Advisors
11
HighTower Advisors
Illinois
$27K – – –
VKH
12
Virtu KCG Holdings
New York
$22K – – –
BIT
13
BlackRock Institutional Trust
California
$13K – – –
BA
14
BlackRock Advisors
Delaware
$11K – – –
Deutsche Bank
15
Deutsche Bank
Germany
$10K – – –
BIM
16
BlackRock Investment Management
Delaware
$8K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$7K – – –
Wells Fargo
18
Wells Fargo
California
$7K – – –
UBS Group
19
UBS Group
Switzerland
$2K – – –
VIA
20
Vantage Investment Advisors
Pennsylvania
$2K – – –
AIG
21
American International Group
New York
$1K – – –
Bank of America
22
Bank of America
North Carolina
$1K – – –
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$1K – – –
Manulife (Manufacturers Life Insurance)
24
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1 – – –
CC
25
Callan Capital
California
– -$52K – –
1
2

HEPA Hedge Fund Activity: Q3 2015 in Review

3 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2015, worth a combined $7.45M — up 136% from $3.16M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new HEPA positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $2.36M. The largest seller was Eidelman Virant Capital, cutting an estimated $76K.

  • 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2015, up from 1 in Q2 2015.
  • Funds reported $7.45M of Hepion Pharmaceuticals stock for Q3 2015, up 136% quarter-over-quarter.
  • 2 funds opened new Hepion Pharmaceuticals positions in Q3 2015 and 0 closed out, a net change of +2 holders.
  • The largest Hepion Pharmaceuticals buyer in Q3 2015 was EAM Investors, an estimated $2.36M added.
  • The largest Hepion Pharmaceuticals seller in Q3 2015 was Eidelman Virant Capital, an estimated $76K sold.

Based on aggregated 13F filings for Q3 2015.